MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Quotient Limited Accounts Receivables 2011-2026 | QTNT
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.32 M | 5.4 M | 3.35 M | 2.86 M | 2.56 M | 2.27 M | 1.81 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.4 M | 1.81 M | 3.37 M |
Quarterly Accounts Receivables Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.65 M | 5.18 M | 5.06 M | 6.27 M | 6.15 M | 5 M | 4.45 M | 4.45 M | 4.54 M | 4.54 M | 4.52 M | 5.97 M | 5.04 M | 4.33 M | 4.72 M | 3.35 M | 2.36 M | 2.51 M | 2.88 M | 2.86 M | 2.02 M | 2.46 M | 2.8 M | 2.56 M | 1.64 M | 3.95 M | 2.36 M | 2.27 M | 1.48 M | 2.12 M | 2.21 M | 1.81 M | 2.01 M | 2.65 M | 3.23 M | 2.44 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.65 M | 1.48 M | 3.58 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 29.14 | -3.75 % | $ 326 M |  China |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
4.75 M | $ 1.1 | 0.46 % | $ 1.4 M | USA |
 |
Co-Diagnostics
CODX
|
304 K | - | - | $ 79.8 M | USA |
 |
DarioHealth Corp.
DRIO
|
3.16 M | $ 11.38 | 1.16 % | $ 323 M |  Israel |
 |
DexCom
DXCM
|
1.22 B | $ 70.29 | 8.0 % | $ 27.4 B | USA |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 32.89 | 3.09 % | $ 914 M | USA |
 |
Danaher Corporation
DHR
|
3.54 B | $ 211.14 | -1.74 % | $ 154 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 205.13 | -0.82 % | $ 22.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | China |
 |
Fulgent Genetics
FLGT
|
69 M | $ 23.24 | 1.18 % | $ 703 M | USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
CareDx, Inc
CDNA
|
51.1 M | $ 19.6 | 2.62 % | $ 1.05 B | USA |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
Interpace Biosciences
IDXG
|
8.54 M | $ 1.85 | - | $ 8.12 M | USA |
 |
Exact Sciences Corporation
EXAS
|
249 M | $ 103.32 | 0.09 % | $ 19.1 B | USA |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
Lantheus Holdings
LNTH
|
321 M | $ 68.71 | -0.02 % | $ 4.75 B | USA |
 |
Guardant Health
GH
|
110 M | $ 104.76 | 1.95 % | $ 12.9 B | USA |
 |
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B |  Niderland |
 |
National Research Corporation
NRC
|
12.4 M | $ 12.09 | -5.81 % | $ 297 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
721 M | $ 160.2 | 0.91 % | $ 8.23 B | USA |
 |
IDEXX Laboratories
IDXX
|
474 M | $ 627.58 | 1.68 % | $ 51.8 B | USA |
 |
Illumina
ILMN
|
735 M | $ 115.9 | 1.27 % | $ 18.4 B | USA |
 |
OPKO Health
OPK
|
118 M | $ 1.24 | 2.48 % | $ 861 M | USA |
 |
IQVIA Holdings
IQV
|
3.2 B | $ 166.72 | -1.27 % | $ 30.2 B | USA |
 |
Natera
NTRA
|
244 M | $ 204.66 | -1.53 % | $ 20.1 B | USA |
|
Biodesix
BDSX
|
8.6 M | $ 11.55 | 6.6 % | $ 1.5 B | USA |
 |
Personalis
PSNL
|
8.14 M | $ 8.22 | -2.09 % | $ 487 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.94 B | $ 281.39 | 1.13 % | $ 23.6 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 95.34 | 19.06 % | $ 7.86 B |  Irlanda |
 |
Biomerica
BMRA
|
731 K | $ 2.25 | 4.19 % | $ 5.17 M | USA |
 |
Bioventus
BVS
|
123 M | $ 8.22 | 1.48 % | $ 515 M | USA |
 |
Medpace Holdings
MEDP
|
402 M | $ 429.09 | 3.14 % | $ 12.4 B | USA |